Bladder Cancer Clinical Trial
Official title:
Development and Validation of a Simulator-based Test in Transurethral Resection of Bladder Tumors
Bladder cancer (BC) is the seventh most common cancer in men worldwide and fourth most common
cancer among Danish men. BC is estimated to be the most cost expensive cancer pr. patient
life. BC is diagnosed, staged and if possible treated with a transurethral bladder tumor
resection (TUR-B).
The prognosis of BC is depending on the depth of invasion, which makes the quality of the
TURB procedure of utmost importance. Retrospective studies from Sweden and Canada on resident
involvement in TURB procedures indicated that the TURBs were insufficient with regard to
staging and had a higher need of repeating TURB.
Surgical training for TURB in Denmark today is based on the Halstedian principle: "See one,
do one, teach one", comparable to training in Sweden and Canada. Thus, there is a need to
develop better and safer principles for training.
Simulators for surgical procedures have a promising role in the surgical training. The
project will explore the effect of simulation training on the quality in transurethral
resection of bladder tumors.
Based on our findings the principles of simulator training will be integrated in a curriculum
for simulator-based TURB training for urological surgeons in Denmark.
The collaboration research group is composed of medical doctors in urological surgery at
Urological Department at Zealand University Hospital, Roskilde (ROS) and experts in medical
simulation at Copenhagen Academy for Medical Education and Simulation at Rigshospitalet
(CAMES).
The incidence of bladder tumors is increasing and is more than 2,000 in Denmark. The bladder
tumor is initially treated by transurethral resection (TURB) classifying the tumor by debt of
invasion. The bladder wall is composed of urothelium, lamina propria and muscularis propria
also known as the detrusor muscle. Bladder cancer (BC), defined as detrusor-muscle invasive
tumors, are found in approximately 50% of bladder tumors. BC is the seventh most common
cancer disease among men worldwide, and the fourth most common cancer in men in Denmark.
Superficial bladder tumors can be treated with TURB whereas BC is treated with radical
cystectomy. Thus, it is of utmost importance that TURB is done with sufficient resection of
the detrusor muscle to ensure that the patient is staged correctly to optimise treatment.
TURB was first described and performed by Desormeaux in 1867 and the obstacles for the
surgeon remain the same more the 150 years after. TUR-B demands haptic skills, the ability to
identify the layers of the bladder wall, the ability to perceive the stiffness of the tissue
through radial and tangential movements and the ability to translate two-dimensional pictures
to a three-dimensional understanding and at the same time move surgical instruments around an
axis.
As TUR-B is performed through the urethra with one scope only, the learner is left with
observation of the master until the day occurs where the learner is trusted the scope. Thus,
the gap between seeing and doing TURB remains significant.
The outcome of TURB have been shown to be dependent on surgeon-experience, with a higher risk
for insufficient resections with lower surgeon experience. A recent Canadian study from a
single centre showed that resident involvement in TUR-B had fewer complete resections
including the detrusor muscle layer in the pathological specimen and patients had delayed
time to cystectomy when compared to patients who had the TUR-B performed by attending
urologists. Thus, both patient safety and quality of care are compromised when residents are
involved in the treatment and staging of patients with bladder tumors.
The current education in TURB in Denmark is based on classical apprenticeship as it has been
for the last 150 years, with the resident learning from a supervisor while performing TURB on
patients.
Needs assessment analyses among specialists in urology and medical education in Denmark in
2017 identified TURB as a procedure in which simulation based skill acquisition are desired.
Simulation-based training is increasingly used in medical education. The opportunity to train
a procedure repeatedly in a secure, stress-free environment with several different scenarios
is appealing. Even though simulation-based training carries these promising opportunities,
the challenge, when introducing simulation-based training, is to identify if the training
transfer to actually improved performance on patients. Thus, we need to test if the simulator
training leads to a level of minimum competency before progressing to performance on
patients. A minimum passing standard should not be defined by amount of training, but by
simulator performance outcomes.
Thus, we need to define test outcomes that identify competency before introducing a
simulation-based test. Mastery learning (ML) is an educational theory in which the learner is
to train until reaching a minimum acquisition level. The endpoint of the training is hereby a
predefined competency level, and not an arbitrary amount of training hours. In the light of
the ML framework the principle of directed self-regulated learning (DSRL) has evoked. DSRL is
a learning-approach where the student regulates his/her own progress through a defined
training protocol without guidance from an instructor. The theory is that this approach
provides the student the opportunity to develop own strategies and to learn from mistakes,
while also increasing the availability of training independent of supervision from a busy
faculty.(20) DSRL can be modified to ensure that the learner do not learn unappropriated
methods by either written theoretical material, video instructions, a non-expert assistant or
all of them. Thus, the purpose of this trial is to develop and gather validity evidence for a
simulator-based test in TURB based on the principles of ML and DSRL.
Hypothesis Overall: A simulator-based test can identify competency-levels with regard to a
score based simulator metrics.
Aim of project To develop and gather validity evidence for a simulator-based test in TURB.
Research Question
- Can the test discriminate between varying competency levels?
- Can we establish a level of competency by a test in simulator-based TURB training?
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |